TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
First Tracks Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$36.28+1.82 (+5.28%)
Close on Oct 19, 2026
- Market cap
- $1.27B
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
10 of First Tracks Biotherapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 8-K | Oct 19, 2026 | Oct 20, 2026 | SEC EDGAR |
| Current report | 8-K | Oct 15, 2026 | Oct 15, 2026 | SEC EDGAR |
| Current report | 8-K | Oct 12, 2026 | Oct 13, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 12, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 12, 2026 | Aug 12, 2026 | SEC EDGAR |
| Current report | 8-K | Jun 15, 2026 | Jun 22, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 14, 2026 | SEC EDGAR |
| Current report | 8-K | May 14, 2026 | May 14, 2026 | SEC EDGAR |
| Current report | 8-K | Apr 20, 2026 | Apr 20, 2026 | SEC EDGAR |
| Current report | 8-K | Apr 1, 2026 | Apr 3, 2026 | SEC EDGAR |